Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gli1-siRNA
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratumoral, Intraperitoneal, Intravenous
01
Overview
Gli1-siRNA is a small interfering RNA (siRNA) designed to silence the expression of the GLI family zinc finger 1 (GLI1) gene. GLI1 is a key transcription factor and terminal effector of the Hedgehog (Hh) signaling pathway, which plays a critical role in cell proliferation, differentiation, and the maintenance of cancer stem cells. In preclinical research, particularly in glioblastoma models, Gli1-siRNA has been shown to inhibit tumorsphere formation and reduce the expression of stemness markers such as CD133, ALDH1, and Nanog. By knocking down GLI1, this agent disrupts the Hh/GLI1 signaling axis, potentially overcoming resistance to chemotherapy and preventing tumor relapse. It is primarily used as a research tool to investigate the role of the Hedgehog pathway in various cancers.
- Other names
- GLI1 siRNAGLI-1 siRNAGLI 1 siRNAsiRNA targeting GLI1
02
Targets
GLI1
Beyond the preview
Go deeper on Gli1-siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Gli1-siRNA.